Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood

• Published in: Frontiers in molecular neuroscience Vol. 14; p. 778955
• Main Authors: Guo, Yuxin, Hu, Zhiyuan, Wang, Zihua
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 23.12.2021; Frontiers Media S.A
• Subjects: Alzheimer's disease; Antibodies; Binding sites; Biomarkers; Biosensors; blood biomarkers; Brain; Brain injury; Cognitive ability; Diagnosis; Enzymes; High-throughput screening; Molecular Neuroscience; Nanomaterials; Neurodegeneration; Neurodegenerative diseases; peptide; Peptides; peptoid; Primary care; Proteins; diagnosis; peptide; blood biomarkers; Alzheimer’s disease; peptoid
• ISSN: 1662-5099; 1662-5099
• DOI: 10.3389/fnmol.2021.778955

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases with irreversible damage of the brain and a continuous pathophysiological process. Early detection and accurate diagnosis are essential for the early intervention of AD. Precise detection of blood biomarkers related to AD could provide a shortcut to identifying early-stage patients before symptoms. In recent years, targeting peptides or peptoids have been chosen as recognition elements in nano-sensors or fluorescence detection to increase the targeting specificity, while peptide-based probes were also developed considering their specific advantages. Peptide-based sensors and probes have been developed according to different strategies, such as natural receptors, high-throughput screening, or artificial design for AD detection. This review will briefly summarize the recent developments and trends of AD diagnosis platforms based on peptide and peptoid as recognition elements and provide insights into the application of peptide and peptoid with different sources and characteristics in the diagnosis of AD biomarkers.